Neogenomics (NEO) Research & Development (2011 - 2026)

Neogenomics has reported Research & Development for 16 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 6.35% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $36.4 million (up 8.04% YoY), and the FY2025 full-year result was $37.1 million, up 18.99% from the prior year.
• Research & Development for Q1 2026 stood at $9.5 million, up from $9.2 million in the prior quarter.
• The five-year high for Research & Development was $10.2 million in Q1 2025, with the low at $5.3 million in Q3 2023.
• Historically, Research & Development has averaged $8.0 million across 5 years, with a median of $7.7 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development jumped 214.05% — and 2023, when it fell 27.72%.
• Neogenomics' Research & Development stood at $6.7 million in 2022, then increased by 6.77% to $7.1 million in 2023, then grew by 11.81% to $8.0 million in 2024, then grew by 15.18% to $9.2 million in 2025, then gained by 3.87% to $9.5 million in 2026.
• The last three Research & Development figures came in at $9.5 million (Q1 2026), $9.2 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.